Baudax Bio, Inc. (BXRXQ)
OTC PINK OTC PINK Primary Summary
Baudax Bio, Inc. (BXRXQ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Baudax Bio, Inc. ever had a stock split?
Baudax Bio, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Gerri Henwood CEO | OTC PINK Exchange | 07160F404 CUSIP |
| US Country | 9 Employees | - Last Dividend | 1 Dec 2022 Last Split | - IPO Date |
Overview
Baudax Bio, Inc. is a pharmaceutical company focused on the development and commercialization of products primarily for hospital and acute care settings. Incorporated in 2019 and headquartered in Malvern, Pennsylvania, Baudax Bio has introduced innovative pain management solutions to the healthcare market. Their flagship product, ANJESO (meloxicam) injection, has been designed for the management of moderate to severe pain. Despite their efforts to contribute to the pharmaceutical industry, on February 22, 2024, Baudax Bio filed for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania, indicating financial distress.
Products and Services
ANJESO (Meloxicam) Injection
ANJESO is an injectable form of meloxicam, a non-steroidal anti-inflammatory drug (NSAID), developed for the management of moderate to severe pain. It can be used alone or in combination with other non-NSAID analgesics, offering a new option for pain management in acute care settings. The product emphasizes the company’s focus on addressing the needs of patients undergoing surgical procedures or experiencing acute pain episodes.
BX1000
BX1000 is an intermediate-acting neuromuscular blocking agent (NMB) designed for use in surgical procedures. Currently in phase II clinical trials, BX1000 represents Baudax Bio’s efforts to expand its portfolio in the surgical setting, enhancing the control and management of muscle relaxation during operations.
BX2000
Currently in phase I clinical trials, BX2000 is an ultra-short-acting NMB. This product aims to provide a solution for very short surgical or diagnostic procedures that require quick muscle relaxation with a rapid recovery period. Alongside, the company is developing a proprietary blockade reversal agent to counteract the effects of BX2000 rapidly after the procedure is completed.
BX3000
In the preclinical study stage, BX3000 is a neuromuscular blockade (NMB) reversal agent. This product is being developed to reverse the effects of neuromuscular blocking agents like BX1000 and BX2000, facilitating quick recovery from muscle relaxation. BX3000 showcases Baudax Bio’s commitment to safety and effectiveness in their neuromuscular management portfolio.
